Kala Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Kala Pharmaceuticals's estimated annual revenue is currently $11.6M per year.
- Kala Pharmaceuticals received $110.0M in venture funding in October 2018.
- Kala Pharmaceuticals's estimated revenue per employee is $126,304
- Kala Pharmaceuticals's total funding is $506.4M.
- Kala Pharmaceuticals's current valuation is $66.2M. (January 2022)
- Kala Pharmaceuticals has 92 Employees.
- Kala Pharmaceuticals grew their employee count by -55% last year.
Kala Pharmaceuticals Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Kala Pharmaceuticals?
Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. For more information, please visit Kala's website at www.kalarx.com.keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Security,Wind Power
Number of Employees
Employee Growth %
Kala Pharmaceuticals News
InvestorsObserver is giving Kala Pharmaceuticals Inc (KALA) an Analyst Rating Rank of 27, meaning KALA is ranked higher by analysts than 27%...
Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for...
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update. Published: Mar 29, 2022. -- Achieved $11.2...
WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has changed the time of ...
-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing -- -- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial -- -- Kala expects to init ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Kala Pharmaceuticals Funding
|2012-03-15||$6.2M||Undisclosed||Lux Capital, Polaris Venture Partners||Article|
|2013-03-01||$11.5M||A||Crown Venture Fund LLC||Article|
|2018-10-03||$110.0M||Undisclosed||Athyrium Capital Management||Article|